ONCOLYTICS BIOTECH INC
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2021 Ended Dec 31, 2021 | Mar 3, 2022 | After market close | – | – | – |
Press releases
Announcements Oncolytics Biotech filed with the SEC
Oncolytics Biotech ® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Other events · EX-99.1 to Form 8-K
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Other events · EX-99.1 to Form 8-K
Domicile Change to the United States
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Oncolytics Biotech ® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Launches Randomized Colorectal Cancer Study
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Other events · EX-99.1 to Form 8-K
Oncolytics Biotech ® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Other events · EX-99.1 to Form 8-K
John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Other events · EX-99.1 to Form 8-K
Update on Intellectual Property Strategy and Patent Filings
Other events · EX-99.1 to Form 8-K
Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Other events · EX-99.2 to Form 8-K
Oncolytics Biotech ® Provides Update on Special Meeting of Shareholders
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
I, Jared Kelly, CEO of Oncolytics Biotech Inc., certify the following:
EX-99.3 to Form 6-K
a transformative dsRNA immunotherapy platform
EX-99.1 to Form 6-K
Oncolytics Biotech ® Announces Upcoming Investor Conferences in September
EX-99.1 to Form 6-K